COPD

Latest News


Don Sin, MD

Blood eosinophil count is a promising biomarker and example of the pathway toward precision medicine in chronic obstructive pulmonary disease (COPD), said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.

On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.

Focusing therapeutic trials on 1 subtype of chronic obstructive pulmonary disease (COPD) can help lead to smaller, targeted studies, which in can help advance precision medicine, said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.

Older adults with coexisting asthma and chronic obstructive pulmonary disease (COPD), known as asthma-COPD overlap, who take fixed-dose combinations of inhaled corticosteroids and long-acting β agonists may be less likely to have persistent low adherence to initial maintenance therapy.

black and white chalk graphic of lung

A report suggests that people with chronic obstructive pulmonary disease (COPD) and asthma have a protein in their lungs that leaks a small molecule into their bloodstream that restricts their breathing instead of relaxing their airways.

Worsening chronic obstructive pulmonary disease (COPD) symptoms are often underreported by patients who cannot recognize these changes as sign of decline, but they can be objectively measured through remote patient monitoring (RPM).